|Articles|July 27, 2023

DIA 2023: What is Biofourmis Currently Working on with CancerX?

In an interview at the 2023 DIA annual meeting with ACT editor, Andy Studna, Jaydev Thakkar, chief operating officer, Biofourmis, disucsses how Biofourmis is working with CancerX to address the financial burden cancer treatment can place on patients.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

2026 DIA Global Annual Meeting: Why Federated Learning Reduces Friction

June 26th 2026

Sponsored Content

Applied Clinical Trials at the 2026 DIA Global Annual Meeting: Conversations on Data, Outsourcing, and the Patient Voice

ByAndy Studna, Senior Editor

June 26th 2026

Jonathan Andrus, CRIO, on Why Site-Sponsor Data Fragmentation Persists and What Central eSource Can Do About It

ByJonathan Andrus,Andy Studna, Senior Editor

June 25th 2026

2026 DIA Global Annual Meeting: On Leadership, Obesity, and the Science That's Redefining What's Possible

ByMarwan Fathallah,Andy Studna, Senior Editor

June 24th 2026

2026 DIA Global Annual Meeting: Where Mixed Models Create the Most Value—and What It Takes to Make Them Work

BySamantha Hadfield,Nick Scott,Andy Studna, Senior Editor

June 22nd 2026

Trending on Applied Clinical Trials Online

Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway

Where AI Is Delivering Real Value in Clinical Trial Payments Right Now

From Doing to Reviewing: How a Connected Ecosystem Streamlines Clinical Trial Finance

Connected Trial Execution: Why Integrating IRT, eCOA and Clinical Supply Matters More Than Ever

ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing